Visualitza per autor "Gavilá Gregori, Joaquín"
Ara mostrant els elements 1-3 d 3
-
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
Gavilá Gregori, Joaquín; Antunes de Melo Oliveira, Ana Mafalda; Pascual, Tomás; Pérez García, José; Gonzàlez, Xavier; Canes, Jordi (BMC, 2019-01-09) -
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
Chacón López‑Muñiz, J. I.; de la Cruz-Merino, Luis; Gavilá Gregori, Joaquín; Martínez Dueñas, E.; Antunes de Melo Oliveira, Ana Mafalda; Seguí Palmer, M. A.; Bellet Ezquerra, Meritxell (Springer, 2019-01) -
SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer
Pascual, Tomás; Antunes de Melo Oliveira, Ana Mafalda; Ciruelos, Eva; Gavilá Gregori, Joaquín; Espinosa Bravo, Martin; Arumí De Dios, Míriam; Bellet Ezquerra, Meritxell; Saura Manich, Cristina (Frontiers Media, 2021-04)